The Food and Drug Administration announced Thursday its approval of suzetrigine, the first new painkiller greenlit by the agency since 1998.
Apple stock rises after the tech giant posts better-than-expected earnings and guides for solid growth, Intel edges higher ...
One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which she experienced when taking opioids.
FRIDAY, Jan. 31, 2025 (HealthDay News) -- The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain ...
The medication offers relatively modest pain relief, underscoring the challenges of finding new ways to manage pain.
The Food and Drug Administration (FDA) has approved Journavxâ„¢ (suzetrigine) for the treatment of moderate to severe acute pain in adults.
Vertex Pharmaceuticals Up Nearly 6%, on Pace for Largest Percent Increase Since December 2023 — Data Talk Vertex Pharmaceuticals Incorporated (VRTX) is currently at $464.17, up $25.77 or 5.88% --Would ...
The drug represents a new pathway to treating people with pain due to surgeries or traumatic injuries, avoiding the addictive ...
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) stock is up 6% at $465.02 at last glance, after the U.S. Food and Drug ...